Moving beyond single-agent checkpoint inhibition in biliary tract cancers: what is the next frontier?
Immunotherapy
; 15(7): 531-540, 2023 05.
Article
em En
| MEDLINE
| ID: mdl-37096922
New treatment strategies for advanced biliary cancers with chemoimmunotherapy combinations have been shown to lead to better tumor responses and overall survival compared with chemotherapy alone. The combination of durvalumab, cisplatin and gemcitabine may become a new standard of care for advanced disease despite the modest improvement in median overall survival of less than 2 months. Promising combinations with anti-CTLA-4 antibodies or antiangiogenics are underway with the objective of improvement in survival. Although multiple combinations are available with the potential to establish a new standard of care, concerns regarding toxicities should also be evaluated. In this review, we will discuss the most important studies involving immunotherapy in biliary cancers as well as future perspectives in the field.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias do Sistema Biliar
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Revista:
Immunotherapy
Assunto da revista:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Brasil
País de publicação:
Reino Unido